Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Harte Hanks (HHS) EBITDA (2016 - 2025)

Harte Hanks has reported EBITDA over the past 16 years, most recently at $709000.0 for Q4 2025.

  • Quarterly EBITDA rose 87.57% to $709000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.2 million through Dec 2025, down 1219.39% year-over-year, with the annual reading at -$2.2 million for FY2025, 1219.39% down from the prior year.
  • EBITDA was $709000.0 for Q4 2025 at Harte Hanks, up from -$2.5 million in the prior quarter.
  • Over five years, EBITDA peaked at $30.6 million in Q4 2022 and troughed at -$2.5 million in Q3 2025.
  • The 5-year median for EBITDA is $635500.0 (2023), against an average of $3.5 million.
  • Year-over-year, EBITDA surged 3330.77% in 2021 and then tumbled 1156.78% in 2025.
  • A 5-year view of EBITDA shows it stood at $13.3 million in 2021, then skyrocketed by 130.47% to $30.6 million in 2022, then plummeted by 102.71% to -$831000.0 in 2023, then soared by 145.49% to $378000.0 in 2024, then skyrocketed by 87.57% to $709000.0 in 2025.
  • Per Business Quant, the three most recent readings for HHS's EBITDA are $709000.0 (Q4 2025), -$2.5 million (Q3 2025), and -$218000.0 (Q2 2025).